TrialSignal
Clinical trial intelligence report
A Phase 1, First-in-Human, Randomized, Observer-blind, Controlled, Dose-ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of a Self-Amplifying mRNA Seasonal Influenza Vaccine (ARCT-2138), When Administered to Healthy Adults
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT06125691-Jul 28, 2026
NCT ID
NCT06125691
Status
COMPLETED
Phase
Phase 1
Sponsor
Arcturus Therapeutics, Inc.
Executive brief
Investment-Ready Snapshot
Arcturus Therapeutics, Inc. is advancing ARCT-2138, a self-amplifying mRNA vaccine for seasonal influenza, through a Phase 1 clinical trial. This innovative approach leverages mRNA technology, which has gained significant traction due to its success in COVID-19 vaccines. The market for seasonal influenza vaccines is substantial, with ongoing demand for improved efficacy and safety profiles. The competitive landscape includes established players like Seqirus and Sanofi, which may pose challenges. Successful trial outcomes could position Arcturus favorably for partnerships or acquisitions, enhancing its market presence in the vaccine sector.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT06125691
Indication
Influenza, Human
Modality
protein therapy
Target
Self-amplifying mRNA platform targeting seasonal influenza virus antigens.
Intervention
ARCT-2138, Licensed Quadrivalent Vaccine for younger adults, Licensed Quadrivalent Vaccine for older adults
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.